Nancy L. Bartlett, MD

Nancy L. Bartlett, MD

Koman Professor of Medical Oncology

Division of Oncology
Mail Stop 8056-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110

11th Floor Mid Campus Center (office)

Teresa Weidner

Research Interests
  • Non-Hodgkin’s lymphoma
  • Hodgkin’s disease
  • Chronic lymphocytic leukemia

My research focuses on the design, conduct, and analysis of clinical trials evaluating new treatments for patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL), including investigator-initiated, pharmaceutical and cooperative group trials. I have been Vice-Chair of the CALGB/Alliance Lymphoma Committee for more than 10 years, where I have served as PI or Co-PI of several Phase II studies and mentored young investigators during trial design and analysis. I serve as the Principal Investigator of the Washington University/Siteman Cancer Center NCTN U10 grant, engaging senior, mid-level, junior investigators and fellows in the National Clinical Trials Network mission. I work closely with the pharmaceutical company SeaGen testing the anti-CD30 based antibody drug conjugate, brentuximab vedotin (BV), for both HL and NHL including efforts to combine BV with chemotherapy and/or PD-1 inhibitors as first line therapy in HL and with lenalidomide in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Our investigator-initiated phase I/dose expansion study of BV and lenalidomide in relapsed DLBCL serves as the experimental arm of an ongoing company-sponsored randomized Phase 3 study. I have ongoing collaborations investigating immunotherapy approaches for lymphoma including 1) the bispecific antibodies (T-cell engagers) mosunetuzumab and glofitimab for R/R B-cell lymphomas, 2) CAR-T cell therapy in R/R DLBCL, 3) personalized neo-antigen vaccines in combination with nivolumab in R/R follicular lymphoma, 4) anti-CD47 antibodies in R/R B-cell lymphomas, and 5) azacytidine or venetoclax in combination with chemotherapy for DLBCL. In addition to my interest in clinical trial development, I have worked closely with other Washington University investigators on exome sequencing of Hodgkin, follicular and transformed large cell lymphoma.



  • 1986: MD, Washington University, St. Louis, MO
  • 1979: MS in Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA
  • 1978: BS in Chemical Engineering, Stanford University, Stanford, CA

Post-Graduate Training

  • 1994-1990: Postdoctoral Fellowship in Medical Oncology, Stanford University, Stanford, CA
  • 1990-1989: Chief Resident in Internal Medicine, University of California, San Francisco, CA
  • 1989-1987: Residency in Internal Medicine, University of California, San Francisco, CA
  • 1987-1986: Internship in Internal Medicine, University of California, San Francisco, CA

Academic Positions

  • present-2008: Professor of Medicine, Washington University, St. Louis, MO
  • 2008-2001: Associate Professor of Medicine, Washington University, St. Louis, MO
  • 2001-1994: Assistant Professor, Washington University, St. Louis, MO

Appointments & Committees

  • present-2016: Washington University Medical School Admissions Committee
  • present-2015: Committee on Research Integrity
  • present-2001: Chairman, Quality Assurance and Safety Monitoring Committee, Siteman Cancer Center
  • present-1994: Staff Physician, Barnes-Jewish Hospital
  • 2001-1999: Protocol Review and Monitoring Committee, Siteman Cancer Center
  • 1998: Electronic Medical Record Committee

Board Certification

  • 2013: Recertification: Medical Oncology
  • 2003: Recertification: Medical Oncology
  • 1993: Board Certified: Medical Oncology
  • 1989: Diplomate, American Board of Internal Medicine

Honors & Awards

  • 2019: Lifetime “Master Physician” Achievement Award from Barnes Jewish Hospital
  • 2018: The Leukemia & Lymphoma Society Gateway Chapter Legacy Leadership Award
  • 2018-2009: Highest Patient Satisfaction Award, Washington University
  • 2017: Teacher of the Year Award in the Hematology-Oncology Fellowship Program, Washington University
  • 2016: Washington University Medical School Alumni Achievement Award
  • 2016: Health Career Accomplishment Recognition Award from the Healthcare Women’s Business Association
  • 2014: Richard L. Schilsky CALGB Achievement Award
  • 2009: Koman Professor of Medical Oncology, Washington University
  • 1999-1996: American Cancer Society Career Development Award
  • 1992: Lymphoma Research Foundation Fellowship
  • 1986: Alpha Omega Alpha
  • 1978: Phi Beta Kappa

Professional Societies, Organizations & Appointments

  • present-2018: Scientific Program Committee – ASCO
  • present-2015: Member, NCI Lymphoma Steering Committee
  • present-2014: Principal Investigator, NCTN LAPS Grant
  • present-2010: National Comprehensive Cancer Network, Non-Hodgkin’s Lymphoma Panel
  • present-2010: Scientific Advisory Board of the Lymphoma Research Foundation
  • present-2010: AIDS Malignancy Consortium, Data Safety Monitoring Board
  • present-2010: Board of Directors, Gateway Chapter Leukemia Lymphoma Society
  • present-2003: Vice-Chair, CALGB/Alliance Lymphoma Core Committee
  • present-1998: Washington University CALGB Principal Investigator
  • present-1998: Member, CALGB Lymphoma Core Committee
  • present-1998: CALGB Board of Directors
  • present-1995: American Society of Clinical Oncology
  • present-1994: American Society of Hematology
  • present-1994: Member, Cancer and Leukemia Group B (CALGB)
  • present-1989: American College of Physicians
  • 2013-2012: Member, ASCO Cancer Education Committee
  • 2012-2011: Hodgkin’s Lymphoma Working Group – a Subcommittee of the NCI Lymphoma Steering Committee
  • 2010-2007: Scientific Program Committee, American Society of Clinical Oncology
  • 2010-2006: Member, CALGB Membership Committee
  • 2007-2004: Editorial Board, Journal of Clinical Oncology
  • 2005-2003: American Society of Clinical Oncology Program Committee, Adult Leukemia/Lymphoma Subcommittee
  • 2002-2000: CALGB Executive Committee